ELECTRONIC DEVICES AND LIQUIDS FOR AEROSOLIZING AND INHALING THEREWITH

Abstract

An electronic device includes a mouthpiece, a bladder, and a mesh assembly having a mesh material and a piezoelectric material. The mesh material is in contact with a liquid of the bladder. The mouthpiece, the bladder, and the mesh assembly are located in-line along a longitudinal axis of the device between opposite longitudinal ends of the device, with the mesh assembly extending between and separating the mouthpiece and the bladder. A liquid-filled cartridge also is disclosed for use with an electronic device and includes a bladder; and a liquid contained within the container for aerosolizing and inhaling by a person using the electronic device. The liquid includes an aqueous formulation including a saline component, an acid component, and a nicotine component. The acid component includes a lactic acid. The aqueous formulation optionally includes one or more of a menthol component, an ethanol component, and a surfactant component.

Claims

1. An electronic device for producing an aerosol for inhalation by a person, comprising: (a) a cartridge assembly; and (b) a handheld base assembly; (c) wherein the cartridge assembly and handheld base assembly are configured to removably couple together.

2. The electronic device of claim 1, wherein the cartridge assembly comprises, (a) a mouthpiece; (b) a cartridge; and (c) a bladder assembly.

3. The electronic device of claim 2, wherein the bladder assembly comprises, (a) a bladder; (b) a wick contained within the bladder; and (c) a mesh assembly; (d) wherein the mesh assembly comprises a mesh material and a piezoelectric material, the mesh material being configured to vibrate when the piezoelectric material is actuated whereby an aerosol is produced when the mesh material contacts a liquid of the bladder such that the aerosol may be inhaled through the mouthpiece.

4. The electronic device of claim 3, wherein the handheld base assembly comprises circuitry and a power supply for actuating the mesh assembly.

5. The electronic device of claim 1, wherein the cartridge assembly and handheld base assembly are configured magnetically couple together.

6. The electronic device of claim 2, wherein the cartridge assembly magnetically mounts onto an end of the handheld base assembly.

7. The electronic device of claim 3, wherein the mesh assembly comprises a piezo mesh disk.

8. The electronic device of claim 3, wherein the wick comprises a lengthwise channel.

9. The electronic device of claim 3, wherein the mesh assembly is disposed on top of a lip of a mouth of the bladder, the bladder extending through an opening in the cartridge to define the mouth.

10. The electronic device of claim 3, wherein the wick is retained in constant contact with the mesh assembly.

11. The electronic device of claim 3, wherein an end of the wick is secured by protuberances extending from walls proximate a bottom of the bladder.

12. A cartridge assembly containing a liquid for producing an aerosol for inhalation by a person, comprising: (a) a mouthpiece; (b) a cartridge; and (c) a bladder assembly.

13. The cartridge assembly of claim 12, wherein the bladder assembly comprises, (a) a bladder; (b) a wick contained within the bladder; and (c) a mesh assembly; (d) wherein the mesh assembly comprises a mesh material and a piezoelectric material, the mesh material being configured to vibrate when the piezoelectric material is actuated whereby an aerosol is produced when the mesh material contacts a liquid of the bladder such that the aerosol may be inhaled through the mouthpiece.

14. The cartridge assembly of claim 13, wherein the mesh assembly comprises a piezo mesh disk.

15. The cartridge assembly of claim 13, wherein the wick comprises a lengthwise channel.

16. The cartridge assembly of claim 13, wherein the mesh assembly is disposed on top of a lip of a mouth of the bladder, the bladder extending through an opening in the cartridge to define the mouth.

17. The cartridge assembly of claim 13, wherein the wick is retained in constant contact with the mesh assembly.

18. The cartridge assembly of claim 13, wherein an end of the wick is secured by protuberances extending from walls of the bladder proximate a bottom of the bladder.

19. The cartridge assembly of claim 13, wherein the liquid contained in the bladder comprises an aqueous formulation, comprising: a saline component; an acid component, wherein the acid component includes a lactic acid; and a nicotine component.

20. The cartridge assembly of claim 19, wherein the saline component includes a 0.9% NaCl saline solution.

21. The cartridge assembly of claim 19, wherein the saline component is approximately 30% by mass to approximately 99.998% by mass of the formulation.

22. The cartridge assembly of claim 19, wherein the acid component further includes one or more of benzoic acid, malic acid, tartaric acid, salicylic acid, levulinic acid, and hydrochloric acid.

23. The cartridge assembly of claim 19, wherein the acid component is approximately 0.001% by mass to approximately 25% by mass of the formulation.

24. The cartridge assembly of claim 19, wherein the nicotine component includes nicotine in a protonated form and nicotine in an unprotonated form.

25. The cartridge assembly of claim 19, wherein the nicotine component is approximately 0.001% by mass to approximately 5% by mass of the formulation.

26. The cartridge assembly of claim 19, wherein a pH value of the aqueous formulation measures between approximately 2 and approximately 5.

27. The cartridge assembly of claim 19, wherein the pH value of the aqueous formulation measures approximately 3.38.

28. The cartridge assembly of claim 19, further comprising a menthol component.

29. The cartridge assembly of claim 28, wherein the menthol component is approximately 0.001% by mass to approximately 15% by mass of the formulation.

30. The cartridge assembly of claim 28, further comprising an ethanol component.

31. The cartridge assembly of claim 30, wherein the ethanol component is approximately 0.001% by mass to approximately 10% by mass of the formulation.

32. The cartridge assembly of claim 28, further comprising a surfactant component, wherein the surfactant component includes one or more different surfactants.

33. The cartridge assembly of claim 32, wherein the surfactant component includes one or more of polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monolaurate, lecithin, and a poloxamer.

34. The cartridge assembly of claim 32, wherein the surfactant component is approximately 0.001% by mass to approximately 10% by mass of the formulation.

35. The cartridge assembly of claim 28, wherein the aqueous formulation further comprises an ethanol component and a surfactant component.

36. An electronic device as disclosed herein.

37. A cartridge assembly as disclosed herein.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0052] One or more preferred embodiments of the invention now will be described in detail with reference to the accompanying drawings, wherein the same elements are referred to with the same reference numerals.

[0053] FIG. 1A illustrates an electronic device having a handheld base assembly and a cartridge assembly, in accordance with one or more preferred implementations of the invention.

[0054] FIG. 1B illustrates the act of separating the handheld base assembly from the cartridge assembly in the electronic device of FIG. 1A.

[0055] FIG. 1C illustrates a close-up view of the cartridge assembly after being separated from the handheld base assembly as illustrated in FIG. 1B.

[0056] FIG. 2A illustrates a front elevational view of the cartridge assembly of FIG. 1C.

[0057] FIG. 2B illustrates a rear elevational view of the cartridge assembly of FIG. 1C.

[0058] FIG. 2C illustrates a perspective view of the rear and a bottom of the cartridge assembly of FIG. 1C.

[0059] FIG. 2D illustrates a perspective view of the bottom of the cartridge assembly of FIG. 1C.

[0060] FIG. 2E illustrates a perspective view of the bottom and a first side of the cartridge assembly of FIG. 1C.

[0061] FIG. 2F illustrates a perspective view of the first side of the cartridge assembly of FIG. 1C.

[0062] FIG. 3A illustrates a perspective view of the first side and a top of the cartridge assembly of FIG. 1C.

[0063] FIG. 3B illustrates a perspective view of the top of the cartridge of FIG. 1C.

[0064] FIG. 3C illustrates a perspective view of the top and a second side of the cartridge assembly of FIG. 1C.

[0065] FIG. 3D illustrates a perspective view of the second side of the cartridge assembly of FIG. 1C.

[0066] FIG. 3E illustrates a perspective view of the second side and the bottom of the cartridge assembly of FIG. 1C.

[0067] FIG. 3F illustrates a perspective view of the front, first side, and top of the cartridge assembly of FIG. 1C.

[0068] FIG. 4A is an exploded view of the cartridge assembly of FIG. 1C.

[0069] FIG. 4B is a perspective view of a top and a rear of a mouthpiece of the cartridge assembly of FIG. 4A.

[0070] FIG. 4C is an elevational view of the rear of the mouthpiece of FIG. 4B.

[0071] FIG. 5A is an elevational view of a front of the cartridge of the cartridge assembly of FIG. 1C.

[0072] FIG. 5B is a perspective view of the front and a top of the cartridge of FIG. 1C.

[0073] FIG. 5C is an exploded perspective view of the front, top, and a first side of the cartridge of FIG. 1C, wherein an O-ring and D-ring are removed from the remainder of the cartridge.

[0074] FIG. 6A is a perspective view of the top and front of the cartridge of FIG. 1C, wherein the O-ring and D-ring have been removed from remainder of the cartridge.

[0075] FIG. 6B is an exploded perspective view of the top, front, and the first side the cartridge of FIG. 1C, wherein two fasteners and a metal plate are removed from the remainder of the cartridge.

[0076] FIG. 6C is a perspective view of the top, side, and a rear of the cartridge of FIG. 6B, wherein the two fasteners and metal plate have been removed from the remainder of the cartridge.

[0077] FIG. 7A is an exploded perspective view of the top, rear, and first side of the cartridge of FIG. 6C, wherein a circuit board is removed from the remainder of the cartridge.

[0078] FIG. 7B is an exploded perspective view of the top, rear, and first side of the cartridge of FIG. 7A, wherein a bladder assembly of the cartridge is removed from the remainder of the cartridge.

[0079] FIG. 8A is a perspective view of a front of the remainder of the cartridge of FIG. 7B after the bladder assembly has been removed.

[0080] FIG. 8B is a perspective view of the front and a first side of the remainder of the cartridge of FIG. 8A.

[0081] FIG. 8C is a perspective view of a rear of the remainder of the cartridge of FIG. 8A.

[0082] FIG. 9 is an exploded perspective view of the bladder assembly of FIG. 7B, wherein the cartridge bladder assembly including a bladder, a wick, and a mesh assembly.

[0083] FIG. 10A is a perspective view of a top of the bladder of FIG. 9.

[0084] FIG. 10B is a perspective view of the top and a front of the bladder of FIG. 9.

[0085] FIG. 10C is a perspective view of the front of the bladder of FIG. 9.

[0086] FIG. 10D is a perspective view of a first side the bladder of FIG. 9.

[0087] FIG. 10E is a perspective view of the top and the first side the bladder of FIG. 9.

[0088] FIG. 11A is the view of FIG. 10A illustrated only with shading.

[0089] FIG. 11B is the view of FIG. 10B illustrated only with shading.

[0090] FIG. 11C is the view of FIG. 10C illustrated only with shading.

[0091] FIG. 11D is the view of FIG. 10D illustrated only with shading.

[0092] FIG. 11E is the view of FIG. 10E illustrated only with shading.

[0093] FIG. 12A is a perspective view illustrated only with shading of the bladder of FIG. 9.

[0094] FIG. 12B is a perspective view illustrated only with shading of the bladder and the wick of FIG. 9.

[0095] FIG. 13A is a top plan view of the wick of FIG. 9.

[0096] FIG. 13B is a side elevational view of the wick of FIG. 9, wherein a longitudinal channel of the wick is shown.

[0097] FIG. 13C is a perspective view of the top and the side of the wick of FIG. 9, wherein the longitudinal channel of the wick is shown.

[0098] FIG. 13D is a perspective view of a bottom and the side of the wick of FIG. 9, wherein the longitudinal channel of the wick is shown.

[0099] FIG. 14A is a top plan view of the mesh assembly of FIG. 9, wherein electrical connections are omitted for clarity.

[0100] FIG. 14B is a perspective view of the top and a side of the mesh assembly of FIG. 14A.

[0101] FIG. 14C is a perspective view of the side and a bottom of the mesh assembly of FIG. 14A.

[0102] FIG. 14D is a bottom plan view of the mesh assembly of FIG. 14A.

[0103] FIG. 15 is a perspective view of the handheld base assembly of FIG. 1B.

[0104] FIG. 16 is the perspective view of the handheld base assembly of FIG. 15, wherein the skin and tail are omitted.

[0105] FIG. 17A is a front elevational view of the handheld base assembly of FIG. 16.

[0106] FIG. 17B is a rear elevational view of the handheld base assembly of FIG. 16.

[0107] FIG. 17C is a top plan view of the handheld base assembly of FIG. 16.

[0108] FIG. 17D is an elevational view of a first side of the handheld base assembly of FIG. 16.

[0109] FIG. 17E is a bottom plan view of the handheld base assembly of FIG. 16.

[0110] FIG. 17F is an elevational view of a second, opposite side of the handheld base assembly of FIG. 16.

[0111] FIG. 18 is the perspective view of FIG. 16, wherein the chassis is further omitted.

[0112] FIG. 19A is a partial, cross-sectional view of a distal end of the front of the handheld base assembly of FIG. 16.

[0113] FIG. 19B is another partial, cross-sectional view of the distal end of the front of the handheld base assembly of FIG. 16.

[0114] FIG. 19C is a partial view of the distal end of the front of the handheld base assembly of FIG. 16 similar to that of FIG. 19 B, but not in cross-section.

[0115] FIG. 20A is a perspective view of the metal plate of FIG. 6B.

[0116] FIG. 20B is a perspective view of the printed circuit board of FIG. 7A.

[0117] FIG. 20C is a front elevational view of the cartridge and printed circuit board, wherein the cartridge is transparently shown.

[0118] FIG. 21 is a view of disassembled components of a cartridge assembly of a prototype commercial embodiment of the invention.

[0119] FIG. 22 is a perspective view of the bladder of the cartridge assembly of FIG. 21.

[0120] FIG. 23 is a perspective view of the bladder of FIG. 22 positioned within the cartridge of FIG. 21.

[0121] FIG. 24A is an elevational view of a top of a prototype commercial embodiment of the invention.

[0122] FIG. 24B is an elevational view of a top of a prototype commercial embodiment of the invention, wherein “WAVE” is being displayed on a display.

[0123] FIG. 24C is an elevational view of the top of the prototype commercial embodiment of the invention, wherein a dose count of 97 is being displayed on the display.

[0124] FIG. 24D is a perspective partial view of the prototype commercial embodiment while a vapor is emitted from the mouthpiece.

[0125] FIG. 24E is a perspective view of the prototype commercial embodiment as an upward force is applied to the cartridge assembly using two fingers while the base assembly is held by the remaining fingers of a hand.

[0126] FIG. 24F is a perspective view of the prototype commercial embodiment following the application of the upward force FIG. 24E, wherein the cartridge assembly has been decoupled and removed from the handheld base assembly.

[0127] FIG. 24G is a view of the prototype commercial embodiment wherein the decoupled cartridge assembly has been inverted to show a bottom thereof.

[0128] FIGS. 25A-25C are structural formulae for unprotonated nicotine, monoprotonated nicotine, and diprotonated nicotine, respectively.

[0129] FIG. 25D is a graphical representation illustrating the relationship between pH and the relative fraction of each species of FIGS. 25A-25C in solution.

[0130] FIG. 26 is a graphical representation illustrating the relationship between total nicotine concentration and an unprotonated fraction of total nicotine and how that relationship can inform a sensory experience.

[0131] FIG. 27 is a graphical representation illustrating a harshness measurement of a menthol-containing formulation as a function of total nicotine concentration.

[0132] FIG. 28 is a flowchart illustrating a method of preparing an aqueous formulation, in accordance with one or more aspects of the invention, which includes a saline component, a nicotine component, and an acid component.

[0133] FIG. 29 is a flowchart illustrating a method of preparing an aqueous formulation, in accordance with one or more aspects of the invention, which includes a saline component, a nicotine component, an acid component, and a menthol component.

[0134] FIG. 30 is a flowchart illustrating a method of preparing an aqueous formulation, in accordance with one or more aspects of the invention, which includes a saline component, a nicotine component, an acid component, a menthol component, and an ethanol component.

[0135] FIG. 31 is a flowchart illustrating a method of preparing an aqueous formulation, in accordance with one or more aspects of the invention, which includes a saline component, a nicotine component, an acid component, a menthol component, an ethanol component, and a surfactant component.

[0136] FIG. 32 discloses aspects and features of a preferred commercial system and apparatus for dosing by patients.

[0137] Further views of a preferred embodiment are contained in the incorporated computer program listing incorporated above by reference, which includes three-dimensional interactive views.

DETAILED DESCRIPTION

[0138] As a preliminary matter, it will readily be understood by one having ordinary skill in the relevant art (“Ordinary Artisan”) that the invention has broad utility and application. Furthermore, any embodiment discussed and identified as being “preferred” is considered to be part of a best mode contemplated for carrying out the invention. Other embodiments also may be discussed for additional illustrative purposes in providing a full and enabling disclosure of the invention. Furthermore, an embodiment of the invention may incorporate only one or a plurality of the aspects of the invention disclosed herein; only one or a plurality of the features disclosed herein; or combination thereof. As such, many embodiments are implicitly disclosed herein and fall within the scope of what is regarded as the invention.

[0139] Accordingly, while the invention is described herein in detail in relation to one or more embodiments, it is to be understood that this disclosure is illustrative and exemplary of the invention and is made merely for the purposes of providing a full and enabling disclosure of the invention. The detailed disclosure herein of one or more embodiments is not intended, nor is to be construed, to limit the scope of patent protection afforded the invention in any claim of a patent issuing here from, which scope is to be defined by the claims and the equivalents thereof. It is not intended that the scope of patent protection afforded the invention be defined by reading into any claim a limitation found herein that does not explicitly appear in the claim itself.

[0140] Thus, for example, any sequence(s) and/or temporal order of steps of various processes or methods that are described herein are illustrative and not restrictive. Accordingly, it should be understood that, although steps of various processes or methods may be shown and described as being in a sequence or temporal order, the steps of any such processes or methods are not limited to being carried out in any particular sequence or order, absent an indication otherwise. Indeed, the steps in such processes or methods generally may be carried out in various different sequences and orders while still falling within the scope of the invention. Accordingly, it is intended that the scope of patent protection afforded the invention be defined by the issued claim(s) rather than the description set forth herein.

[0141] Additionally, it is important to note that each term used herein refers to that which the Ordinary Artisan would understand such term to mean based on the contextual use of such term herein. To the extent that the meaning of a term used herein—as understood by the Ordinary Artisan based on the contextual use of such term—differs in any way from any particular dictionary definition of such term, it is intended that the meaning of the term as understood by the Ordinary Artisan should prevail.

[0142] With regard to the construction of the scope of any claim in the United States, no claim element is to be interpreted under 35 U.S.C. 112(f) unless the explicit phrase “means for” or “step for” is actually used in such claim element, whereupon this statutory provision is intended to and should apply in the interpretation of such claim element. With regard to any method claim including a condition precedent step, such method requires the condition precedent to be met and the step to be performed at least once but not necessarily every time during performance of the claimed method.

[0143] Furthermore, it is important to note that, as used herein, “comprising” is open-ended insofar as that which follows such term is not exclusive. Additionally, “a” and “an” each generally denotes “at least one” but does not exclude a plurality unless the contextual use dictates otherwise. Thus, reference to “a picnic basket having an apple” is the same as “a picnic basket comprising an apple” and “a picnic basket including an apple”, each of which identically describes “a picnic basket having at least one apple” as well as “a picnic basket having apples”; the picnic basket further may contain one or more other items beside an apple. In contrast, reference to “a picnic basket having a single apple” describes “a picnic basket having only one apple”; the picnic basket further may contain one or more other items beside an apple. In contrast, “a picnic basket consisting of an apple” has only a single item contained therein, i.e., one apple; the picnic basket contains no other item.

[0144] When used herein to join a list of items, “or” denotes “at least one of the items” but does not exclude a plurality of items of the list. Thus, reference to “a picnic basket having cheese or crackers” describes “a picnic basket having cheese without crackers”, “a picnic basket having crackers without cheese”, and “a picnic basket having both cheese and crackers”; the picnic basket further may contain one or more other items beside cheese and crackers.

[0145] When used herein to join a list of items, “and” denotes “all of the items of the list”. Thus, reference to “a picnic basket having cheese and crackers” describes “a picnic basket having cheese, wherein the picnic basket further has crackers”, as well as describes “a picnic basket having crackers, wherein the picnic basket further has cheese”; the picnic basket further may contain one or more other items beside cheese and crackers.

[0146] The phrase “at least one” followed by a list of items joined by “and” denotes an item of the list but does not require every item of the list. Thus, “at least one of an apple and an orange” encompasses the following mutually exclusive scenarios: there is an apple but no orange; there is an orange but no apple; and there is both an apple and an orange. In these scenarios if there is an apple, there may be more than one apple, and if there is an orange, there may be more than one orange. Moreover, the phrase “one or more” followed by a list of items joined by “and” is the equivalent of “at least one” followed by the list of items joined by “and”.

[0147] Additionally, as used herein unless context dictates otherwise, the following terms have the following meanings.

[0148] “Liquid” means a substance that flows freely but is of constant volume, generally having a consistency like that of water (lower viscosity) or oil (higher viscosity). Liquid is generic to and encompasses a solution, a suspension, and an emulsion.

[0149] “Solution” means a homogeneous mixture of two or more components. The dissolving agent is the solvent. The substance that is dissolved is the solute. The components of a solution are atoms, ions, or molecules, and the components are usually a nanometer or less in any dimension. An example of a solution is sugar mixed with water.

[0150] “Suspension” means a mixture of components that can be evenly distributed by mechanical methods such as shaking or stirring, but that will eventually settle out over an extended period of time. The components in a suspension are generally larger than those in solutions. An example of a suspension is oil mixed with water.

[0151] “Colloidal dispersion” means a heterogenous liquid mixture in which a component is dispersed in another component and does not tend to settle out over an extended period of time. The dispersed components generally is larger than components of a solution and smaller than components of a suspension.

[0152] “Aerosol” means a colloidal dispersion of a solid or liquid in a gas.

[0153] “Emulsion” means a colloidal dispersion of a liquid in a liquid. An example of an emulsion is milk.

[0154] “Nanoemulsion” means an emulsion in which the dispersed component comprises nanoparticles.

[0155] “Nanoparticle” means a molecule has—or aggregate of molecules have—having no dimension greater than about a micrometer (1,000 nanometers). In accordance with preferred embodiments of aspects and features of the invention, nanoparticles preferably have a dimension of between about 50 and about 200 nanometers.

[0156] “Micelle” means a vesicle having a layer of molecules that encapsulate and transport a substance to cells of a body. The encapsulating molecules in a micelle may be surfactants or polymers, for example. A typical micelle in an aqueous solution forms an aggregate with the hydrophilic “head” regions in contact with the surrounding solvent, creating a hydrophobic tail region in the interior of the aggregate.

[0157] “Liposome” means a vesicle having at least one bilayer of molecules that encapsulates and transports a substance to cells of a body.

[0158] Referring now to the drawings, one or more preferred embodiments in accordance with one or more aspects and features of the invention are next described. The following description of one or more preferred embodiments is merely exemplary in nature and is in no way intended to limit the invention, its implementations, or uses.

[0159] In accordance with electronic devices of the invention, a vibrating mesh is provided for aerosolizing a liquid without smoldering. The aerosolized liquid preferably is in the form of a vapor cloud similar to what a person or observer would surmise to be “vapor” when vaping. In the context of vaping, such preferred devices of the invention therefore are believed to produce an aerosol that is free of undesired carcinogens. This is in stark contrast to vaporizers used today to aerosolize e-liquids by heating the e-liquids and desired compounds contained therein (e.g., nicotine) or supplements such as B12, THC/CBD and other drugs or stimulants. As a result of using heating to aerosolize the e-liquids, these vaporizers produce toxic byproducts like formaldehyde, a recognized Group 1 carcinogen for caner, which toxic byproducts then are unfortunately inhaled by a person using the vaporizer. For example, when the liquids are heated, the liquids undergo a thermochemical reaction producing unwanted emissions. The unwanted emissions of the toxic byproducts may cause bodily harm from extended inhalation exposure.

[0160] By utilizing a vibrating mesh, preferred electronic devices in accordance with one or more aspects and features of the invention produce an aerosol without using heat and thus advantageously avoid such toxic byproducts created by the vaporizes currently on the market. The electronic devices thereby advantageously produce a carcinogen free aerosol free of harmful emission byproducts.

[0161] The preferred electronic devices in accordance with one or more aspects and features of the invention are particularly well suited for aerosolizing a liquid for inhalation without heating and, in particular, for aerosolizing an aqueous formulation including nicotine for inhalation without heating.

[0162] Such a preferred embodiment of an electronic device is illustrated in and described with reference to FIG. 1A through FIG. 20C in accordance with one or more aspect and features of the invention. Components for a prototype cartridge assembly are seen in FIGS. 21, 22A, and 22B. A commercial prototype is seen in FIGS. 23A through 23G. Yet additional views of a preferred embodiment of an electronic device in accordance with one or more aspect and features of the invention are disclosed in the disclosure of the incorporated computer program listing.

[0163] Other forms of an electronic device in accordance with the present invention include vapes, vape pens, and nebulizers. Other terminology may be given to electronic devices of the present invention. In any event, electronic devices of the present invention produce an aerosol for inhalation without smoldering or heating, whatever commercial or consumer name may be given.

[0164] FIG. 1A illustrates an electronic device 100 having a handheld base assembly 102 and a cartridge assembly 104, in accordance with one or more preferred implementations of the invention. The cartridge assembly and handheld base assembly are configured to removably couple together. FIG. 1B illustrates the act of separating the handheld base assembly 102 from the cartridge assembly 104 in the electronic device of FIG. 1A. Preferably, the cartridge assembly magnetically mounts onto an end of the handheld base assembly for decoupling attachment. FIG. 1C illustrates a close-up view of the cartridge assembly 104 after being separated from the handheld base assembly as illustrated in FIG. 1B.

[0165] FIG. 2A illustrates a front elevational view of the cartridge assembly 104 of FIG. 1C. FIG. 2B illustrates a rear elevational view of the cartridge assembly 104 of FIG. 1C. FIG. 2C illustrates a perspective view of the rear and a bottom of the cartridge assembly 104 of FIG. 1C. FIG. 2D illustrates a perspective view of the bottom of the cartridge assembly 104 of FIG. 1C. FIG. 2E illustrates a perspective view of the bottom and a first side of the cartridge assembly 104 of FIG. 1C. FIG. 2F illustrates a perspective view of the first side of the cartridge assembly 104 of FIG. 1C.

[0166] FIG. 3A illustrates a perspective view of the first side and a top of the cartridge assembly 104 of FIG. 1C. FIG. 3B illustrates a perspective view of the top of the cartridge 104 of FIG. 1C. FIG. 3C illustrates a perspective view of the top and a second side of the cartridge assembly 104 of FIG. 1C. FIG. 3D illustrates a perspective view of the second side of the cartridge assembly 104 of FIG. 1C. FIG. 3E illustrates a perspective view of the second side and the bottom of the cartridge assembly 104 of FIG. 1C. FIG. 3F illustrates a perspective view of the front, first side, and top of the cartridge assembly 104 of FIG. 1C.

[0167] The cartridge assembly 104 comprises a mouthpiece 106; and a cartridge 108. FIG. 4A is an exploded view of the cartridge assembly 104 of FIG. 1C, wherein two fasteners 103,105 and the mouthpiece 106 are illustrated being separated from the cartridge 108. FIG. 4B is a perspective view of a top and a rear of a mouthpiece 106 of the cartridge assembly 104 of FIG. 4A. FIG. 4C is an elevational view of the rear of the mouthpiece 106 of FIG. 4B.

[0168] FIG. 5A is an elevational view of a front of the cartridge 108 of the cartridge assembly of FIG. 1C. FIG. 5B is a perspective view of the front and a top of the cartridge 108 of FIG. 1C. FIG. 5C is an exploded perspective view of the front, top, and a first side of the cartridge 108 of FIG. 1C, wherein an O-ring 110 and D-ring 112 are removed from the cartridge 108.

[0169] FIG. 6A is a perspective view of the top and front of the cartridge 108 of FIG. 1C, wherein the O-ring 112 and D-ring 110 have been removed from remainder of the cartridge 108. FIG. 6B is an exploded perspective view of the top, front, and the first side the cartridge 108 of FIG. 1C, wherein two fasteners 111,113 and a metal plate 114 are being separated from the remainder of the cartridge 108. The metal plate 114 is used to couple the cartridge assembly 104 to one or more magnets located in a distal end 140 of the base assembly 102. FIG. 6C is a perspective view of the top, side, and a rear of the cartridge 108 of FIG. 6B, wherein the two fasteners 111,113 and metal plate 114 have been removed from the remainder of the cartridge 108.

[0170] FIG. 7A is an exploded perspective view of the top, rear, and first side of the cartridge 108 of FIG. 6C, wherein a circuit board 116 is removed from the remainder of the cartridge 108. The cartridge assembly 104 comprises a bladder assembly 118, and FIG. 7B is an exploded perspective view of the top, rear, and first side of the cartridge 108 of FIG. 7A, wherein a bladder assembly 118 is removed from the cartridge 108.

[0171] FIG. 8A is a perspective view of a front of the remainder of the cartridge 108 of FIG. 7B after the bladder assembly 118 has been removed. FIG. 8B is a perspective view of the front and a first side of the remainder of the cartridge 108 of FIG. 8A. FIG. 8C is a perspective view of a rear of the remainder of the cartridge 108 of FIG. 8A.

[0172] The bladder assembly 118 comprises a bladder 120; a wick 122 contained within the bladder 120; and a mesh assembly 124. FIG. 9 is an exploded perspective view of the bladder assembly 118 of FIG. 7B. The mesh assembly 124 preferably is disposed on top of a lip of a mouth of the bladder 120, the bladder 120 extending through an opening in the cartridge 108 to define the mouth.

[0173] FIG. 10A is a perspective view of a top of the bladder 120 of FIG. 9. FIG. 10B is a perspective view of the top and a front of the bladder 120 of FIG. 9. FIG. 10C is a perspective view of the front of the bladder 120 of FIG. 9. FIG. 10D is a perspective view of a first side the bladder 120 of FIG. 9. FIG. 10E is a perspective view of the top and the first side the bladder 120 of FIG. 9.

[0174] FIG. 11A is the view of FIG. 10A illustrated only with shading. FIG. 11B is the view of FIG. 10B illustrated only with shading. FIG. 11C is the view of FIG. 10C illustrated only with shading. FIG. 11D is the view of FIG. 10D illustrated only with shading FIG. 11E is the view of FIG. 10E illustrated only with shading.

[0175] FIG. 12A is a perspective view illustrated only with shading of the bladder 120 of FIG. 9.

[0176] FIG. 12B is a perspective view illustrated only with shading of the bladder 120 and the wick 122 of FIG. 9.

[0177] The wick 122 of the bladder assembly 118 preferably comprises a lengthwise channel 126 FIG. 13A is a top plan view of the wick 122 of FIG. 9. FIG. 13B is a side elevational view of the wick 122 of FIG. 9, wherein a longitudinal channel 126 of the wick 122 is shown. FIG. 13C is a perspective view of the top and the side of the wick 122 of FIG. 9, wherein the longitudinal channel 126 of the wick 122 also is shown. FIG. 13D is a perspective view of a bottom and the side of the wick 122 of FIG. 9, wherein the longitudinal channel 126 of the wick 122 again is shown. The channel 126 preferably extends between distal ends of the wick 122 and preferably is an open ended channel at both ends, as shown.

[0178] FIG. 14A is a top plan view of the mesh assembly 124 of FIG. 9, wherein electrical connections are omitted for clarity. FIG. 14B is a perspective view of the top and a side of the mesh assembly 124 of FIG. 14A. FIG. 14C is a perspective view of the side and a bottom of the mesh assembly 124 of FIG. 14A. FIG. 14D is a bottom plan view of the mesh assembly 124 of FIG. 14A.

[0179] The mesh assembly 124 comprises a mesh material and a piezoelectric material; preferably, the mesh assembly 124 comprises a piezo mesh disk. The mesh material is configured to vibrate when the piezoelectric material is actuated, whereby an aerosol is produced when the mesh material contacts a liquid of the bladder 120 such that the aerosol may be inhaled through the mouthpiece 106. The wick 122 preferably is retained in constant contact with the mesh assembly 124. In particular, an end of the wick 122 preferably is secured by the protuberances of the bladder extending from the walls proximate a bottom of the bladder, and the wick has a length such that a distal end of the wick 122 is maintained in contact with the mesh assembly when the bladder assembly 118 is assembled, the opposite end of the wick 122 being held in place by the protuberances of the bladder 120.

[0180] The handheld base assembly 102 comprises circuitry; and a power supply for actuating the mesh assembly 124 when the base assembly 102 and cartridge assembly 104 are coupled together, preferably through the pins that engage electrical contacts when the base assembly 102 and cartridge assembly 104 are coupled. One or more of the pins further are provided for electronic communication between circuitry of the handheld base assembly 102 and non-transitory machine-readable memory located within the cartridge assembly 104.

[0181] FIG. 15 is a perspective view of the handheld base assembly 102 of FIG. 1B.

[0182] FIG. 16 is the perspective view of the handheld base assembly 102 of FIG. 15, wherein the skin 132 and tail 134 are omitted.

[0183] FIG. 17A is a front elevational view of the handheld base assembly 102 of FIG. 16. FIG. 17B is a rear elevational view of the handheld base assembly 102 of FIG. 16. FIG. 17C is a top plan view of the handheld base assembly 102 of FIG. 16. FIG. 17D is an elevational view of a first side of the handheld base assembly 102 of FIG. 16. FIG. 17E is a bottom plan view of the handheld base assembly 102 of FIG. 16. FIG. 17F is an elevational view of a second, opposite side of the handheld base assembly 102 of FIG. 16.

[0184] FIG. 18 is the perspective view of the handheld base assembly 102 of FIG. 16, wherein the chassis 136 is further omitted.

[0185] FIG. 19A is a partial, cross-sectional view of a distal end 140 of the front of the handheld base assembly of FIG. 16. FIG. 19B is another partial, cross-sectional view of the distal end 140 of the front of the handheld base assembly of FIG. 16. FIG. 19C is a partial view of the distal end 140 of the front of the handheld base assembly of FIG. 16 similar to that of FIG. 19 B, but not in cross-section.

[0186] FIG. 20A is a perspective view of the metal plate 114 of FIG. 6B. FIG. 20B is a perspective view of the printed circuit board 116 of FIG. 7A. FIG. 20C is a front elevational view of the cartridge 108 and printed circuit board 116, wherein the cartridge 108 is transparently shown.

[0187] FIG. 21 is a view of disassembled components of a cartridge assembly 204 of a prototype commercial embodiment 200 of the invention.

[0188] FIG. 22 is a perspective view of the bladder 220 of the cartridge assembly 204 of FIG. 21.

[0189] FIG. 23 is a perspective view of the bladder 220 of FIG. 22 positioned within the cartridge 204 of FIG. 21.

[0190] FIG. 24A is an elevational view of a top of the prototype commercial embodiment 200.

[0191] FIG. 24B is an elevational view of a top of a prototype commercial embodiment 200, wherein “WAVE” is being displayed on a display. FIG. 24C is an elevational view of the top of the prototype commercial embodiment 200, wherein a dose count of 97 is being displayed on the display. FIG. 24D is a perspective partial view of the prototype commercial embodiment 200 while a vapor is emitted from the mouthpiece. FIG. 24E is a perspective view of the prototype commercial embodiment 200 as an upward force is applied to the cartridge assembly 204 using two fingers while the base assembly 202 is held by the remaining fingers of a hand. FIG. 24F is a perspective view of the prototype commercial embodiment 200 following the application of the upward force of FIG. 24E, wherein the cartridge assembly 204 has been decoupled and removed from the handheld base assembly 202. FIG. 24G is a view of the prototype commercial embodiment 200, wherein the decoupled cartridge assembly 204 has been inverted to show a bottom thereof.

[0192] With regard to additional aspects, features and embodiments of the invention, the bladder preferably is filled with a liquid comprising an aqueous formulation comprising a saline component; an acid component, wherein the acid component includes a lactic acid; and a nicotine component.

[0193] With reference to FIGS. 25A-31, preferred aqueous formulations for aerosolizing and inhaling are disclosed. In this regard, FIGS. 25A-25C are structural formulae for unprotonated nicotine, monoprotonated nicotine, and diprotonated nicotine, respectively. In its unprotonated (or “free-base”) form, which is depicted in FIG. 25A, nicotine is a weak base having a pK.sub.a value of 8.0. As shown in FIG. 25A, the unprotonated form of nicotine includes two nitrogen atoms that exhibit basic properties. By adding one proton to one of the two nitrogen atoms, the unprotonated form becomes a monoprotonated form, which is depicted in FIG. 25B. Adding another proton to the other of the two nitrogen atoms transitions the monoprotonated form to a diprotonated form, which is depicted in FIG. 25C. In the mono- and diprotonated forms, nicotine is less volatile than the unprotonated form.

[0194] FIG. 25D is a graphical representation illustrating the relationship between pH and the relative fraction of each species of FIGS. 25A-25C in solution. As shown in FIG. 25D, the relative dominance of the unprotonated form in a solution tends to shift in favor of the protonated forms around a pH of 8. At moderately acidic to slightly basic pH values in the approximately 3.5 to approximately 8 range, the monoprotonated form is the dominant species in solution. And, at pH values of approximately 3.5 and lower, the diprotonated form is the dominant species in solution. In this regard, it is contemplated that an acid can be added to unprotonated nicotine to adjust the pH and increase the ratio of protonated nicotine species, which includes both monoprotonated and diprotonated species, in solution.

[0195] FIG. 26 is a graphical representation illustrating the relationship between total nicotine concentration and an unprotonated fraction of total nicotine and how that relationship can inform a sensory experience. As a basic compound, nicotine in its unprotonated form is understood to yield a harsh sensory experience at higher nicotine concentrations. As illustrated in FIG. 26, the harshness of the sensory experience can be mitigated when the fraction of unprotonated nicotine is reduced relative to the overall amount of nicotine present in solution.

[0196] FIG. 27 is a graphical representation illustrating a harshness measurement of a menthol-containing formulation as a function of total nicotine concentration. It is contemplated that a harsh sensory experience arising from nicotine inhalation can be further mitigated by the inclusion of menthol in solution. As depicted in FIG. 27, a menthol concentration of approximately 3.5% can reduce the irritation/harshness sensory effect at higher nicotine concentrations (such as at nicotine concentrations of 18 mg/mL or greater). This mitigation of the harshness effect can be coupled with other favorable characteristics of menthol, including a strong cooling sensation and strong overall intensity.

[0197] With reference to FIGS. 26 and 27, it is contemplated that an overall sensorial appeal of aerosolizable and inhalable aqueous formulations can be informed by considerations of one or more of total nicotine amount, a ratio of unprotonated nicotine relative to the total nicotine amount, and menthol.

[0198] In some contemplated embodiments, an aqueous formulation for aerosolizing and inhaling using electronic devices includes a total nicotine concentration of approximately 20 mg/mL in an aqueous solution. To achieve a desired ratio of unprotonated nicotine to protonated nicotine (including monoprotonated and diprotonated forms) in such a formulation, an acid can be added until an unprotonated fraction of approximately 0.2 to approximately 0.35 is achieved relative to the total nicotine amount. With further reference to FIG. 26, a zone of interest for such a formulation is reflected by the portion of the graphical representation marked by A, with preference given to the portion marked by B. When considered in light of the graphical representation of FIG. 25D, a target pH for achieving an unprotonated fraction of approximately 0.2 to approximately 0.35 falls between the 6 to 8 range. For example, a species that includes approximately 0.3 unprotonated fraction may require a target pH of approximately 7.5, which is depicted in FIG. 25D with a line marked by C. Additionally, it is contemplated that menthol can be included in the formulation to enhance the sensory experience and reduce harshness.

[0199] In other contemplated embodiments, an aqueous formulation for aerosolizing and inhaling using electronic devices includes a saline component, a nicotine component, an acid component, and, optionally, one or both of a menthol component and an ethanol component. Contemplated mass percent ranges for each component for such a formulation include: a saline component having approximately 30% by mass to approximately 99.998% by mass of the solution; a nicotine component having approximately 0.001% by mass to approximately 5% by mass of the solution; an acid component having approximately 0.001% by mass to approximately 25% by mass of the solution; a menthol component having 0% by mass to approximately 15% by mass of the solution; and an ethanol component having 0% by mass to approximately 25% by mass of the solution.

[0200] It is contemplated that the saline component is a safe, aqueous solution that resembles or approximates a physiologically normal solution. One preferred form of saline for use as a saline component in the aqueous formulation is an isotonic saline, such as 0.9% NaCl saline solution. It is further contemplated that hypotonic or hypertonic saline can be used. In this regard, a saline solution may fall within a range of approximately 0.001% to approximately 7.5% NaCl saline solution. In still other contemplated embodiments, water is used in place of a saline component.

[0201] The acid component functions to reduce the fraction of unprotonated nicotine relative to the overall nicotine amount. One preferred acid for use as an acid component in the aqueous formulation is lactic acid. Other contemplated acids include, but are not limited to, benzoic acid, malic acid, tartaric acid, salicylic acid, levulinic acid, and hydrochloric acid.

[0202] As discussed above, menthol can optionally be included in the aqueous formulation to enhance the sensory experience and reduce harshness. Other flavorants and components are likewise contemplated in addition to (or in place of) menthol.

[0203] It is contemplated that ethanol can optionally be included in the aqueous formulation as a surfactant or as a cosolvent. Other contemplated cosolvents include, but are not limited to, propylene glycol and glycerin.

[0204] One specific contemplated formulation in accordance with the above-described features includes: a 0.9% NaCl saline component having approximately 93.486% by mass of the solution; a nicotine component having approximately 2% by mass of the solution; a lactic acid component having approximately 4.477% by mass of the solution; and a menthol component having approximately 0.037% by mass of the solution.

[0205] FIG. 28 is a flowchart illustrating a method 1000 of preparing an aqueous formulation, in accordance with one or more aspects of the invention, which includes a saline component, a nicotine component, and an acid component. In a first step 1005, the nicotine component and the acid component are combined to form a nicotine salt mixture. In embodiments where the acid component includes a lactic acid, the nicotine component and the acid component combine to form a nicotine lactate mixture. In a second step 1010, the nicotine salt mixture is combined with the saline solution to create the target formulation for aerosolizing and inhaling using electronic devices.

[0206] FIG. 29 is a flowchart illustrating a method 2000 of preparing an aqueous formulation, in accordance with one or more aspects of the invention, which includes a saline component, a nicotine component, an acid component, and a menthol component. In a first step 2005, the nicotine component and the acid component are combined to form a nicotine salt mixture. In embodiments where the acid component includes a lactic acid, the nicotine component and the acid component combine to form a nicotine lactate mixture. In a second step 2010, the menthol component is separately combined with the saline component to form a menthol/saline mixture. Then, in a third step 2015, the nicotine salt mixture from the first step 2005 is combined with the menthol/saline mixture from the second step 2010 to create the target formulation for aerosolizing and inhaling using electronic devices.

[0207] FIG. 30 is a flowchart illustrating a method 3000 of preparing an aqueous formulation, in accordance with one or more aspects of the invention, which includes a saline component, a nicotine component, an acid component, a menthol component, and an ethanol component. In a first step 3005, the nicotine component and the acid component are combined to form a nicotine salt mixture. In embodiments where the acid component includes a lactic acid, the nicotine component and the acid component combine to form a nicotine lactate mixture. In a second step 3010, the menthol component is separately combined with the ethanol component to form a menthol/ethanol mixture. As discussed above, it is contemplated that the ethanol component can be included as a surfactant or as a cosolvent. In this regard, it is noted that components added to the solution that are beyond the solubility limit of menthol may require a surfactant. In this regard, it is contemplated that use of a surfactant allows components above a solubility limit to be included in a mixture through formation of an emulsion. Surfactant molecules interrelate to form a structure capable of encapsulating an otherwise insoluble component. In a third step 3015, the menthol/ethanol mixture from the second step 3010 is combined with the saline component to create a menthol/ethanol/saline mixture. Then, in a fourth step 3020, the nicotine salt mixture from the first step 3005 is combined with the menthol/ethanol/saline mixture from the third step 3015 to create the target formulation for aerosolizing and inhaling using electronic devices.

[0208] In still other contemplated embodiments, an aqueous formulation for aerosolizing and inhaling using electronic devices includes a saline component, a nicotine component, an acid component, and, optionally, any one or any combination of a menthol component, an ethanol component, and a surfactant component. Contemplated mass percent ranges for each component for such a formulation include: a saline component having approximately 35% by mass to approximately 99.998% by mass of the solution; a nicotine component having approximately 0.001% by mass to approximately 5% by mass of the solution; an acid component having approximately 0.001% by mass to approximately 25% by mass of the solution; a menthol component having 0% by mass to approximately 15% by mass of the solution; an ethanol component having 0% by mass to approximately 10% by mass of the solution; and a surfactant component having 0% by mass to approximately 10% by mass of the solution.

[0209] It is contemplated that the saline component is a safe, aqueous solution that resembles or approximates a physiologically normal solution. One preferred form of saline for use as a saline component in the aqueous formulation is an isotonic saline, such as 0.9% NaCl saline solution. It is further contemplated that hypotonic or hypertonic saline can be used. In this regard, a saline solution may fall within a range of approximately 0.001% to approximately 7.5% NaCl saline solution. In still other contemplated embodiments, water is used in place of a saline component.

[0210] The acid component functions to reduce the fraction of unprotonated nicotine relative to the overall nicotine amount. One preferred acid for use as an acid component in the aqueous formulation is lactic acid. Other contemplated acids include, but are not limited to, benzoic acid, malic acid, tartaric acid, salicylic acid, levulinic acid, and hydrochloric acid.

[0211] As discussed above, menthol can optionally be included in the aqueous formulation to enhance the sensory experience and reduce harshness. Other flavorants and components are likewise contemplated in addition to (or in place of) menthol.

[0212] It is contemplated that ethanol can optionally be included in the aqueous formulation as a surfactant or as a cosolvent. Other contemplated cosolvents include, but are not limited to, propylene glycol and glycerin.

[0213] The surfactant component can help to reduce the surface tension of the liquid solution in which it is dissolved. Surfactant molecules in solution can group together to form a micelle or liposomal structure to encapsulate target ingredients or components in solution. In this regard, an emulsion or nanoemulsion can be formed so that otherwise insoluble components can be encapsulated by surfactants and remain part of the mixture. In at least some embodiments, it is contemplated that a microfluidics approach (using a microfluidics machine) can be utilized to form a nanoemulsion through the interaction of liquid streams in defined microchannels. For additional discussion of surfactants as encapsulating agents for pulmonary delivery of specific ingredients or components to the alveolar lung by inhalation, reference is made to co-pending and commonly assigned U.S. patent application Ser. No. 17/075,679, which is incorporated by reference herein.

[0214] It is contemplated that surfactants for use in an aqueous formulation in accordance with one or more aspects of the present invention may include, but are not limited to: high purity polyoxyethylene sorbitan monooleate (also known by its trade name, SUPER REFINED® Polysorbate 80); polyoxyethylene sorbitan monooleate; (also known by its trade name, TWEEN® Polysorbate 80); polyoxyethylene sorbitan monostearate (also known by its trade name TWEEN® Polysorbate 60); polyoxyethylene sorbitan monopalmitate (also known by its trade name TWEEN® Polysorbate 40); polyoxyethylene sorbitan monolaurate (also known by its trade name TWEEN® Polysorbate 20); lecithin; dipalmitoylphosphatidylcholine (DPPC); 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); sorbitan monostearate (also known by its trade name SPAN 60); sorbitan monopalmitate (also known by its trade name SPAN 40); and a poloxamer (such as poloxamer 188 or poloxamer 447). It is further contemplated that an aqueous formulation in accordance with one or more aspects of the present invention can include a single surfactant or can include multiple surfactants.

[0215] One specific contemplated formulation in accordance with the above-described features includes: a 0.9% NaCl saline component having approximately 91.291% by mass of the solution; a nicotine component having approximately 2.001% by mass of the solution; a lactic acid component having approximately 4.479% by mass of the solution; a menthol component having approximately 2.229% by mass of the solution; an ethanol component having approximately 1.758% by mass of the solution; and a TWEEN® Polysorbate 80 surfactant component having approximately 2.377% by mass of the solution.

[0216] FIG. 31 is a flowchart illustrating a method 4000 of preparing an aqueous formulation, in accordance with one or more aspects of the invention, which includes a saline component, a nicotine component, an acid component, a menthol component, an ethanol component, and a surfactant component. In a first step 4005, the nicotine component and the acid component are combined to form a nicotine salt mixture. In embodiments where the acid component includes a lactic acid, the nicotine component and the acid component combine to form a nicotine lactate mixture. Then, in a second step 4010, the nicotine salt mixture from the first step 4005 is combined with the saline component to create a nicotine salt/saline mixture. In a third step 4015, the menthol component, the ethanol component, and the surfactant component are separately combined to form a menthol/ethanol/surfactant mixture. In contemplated embodiments, the surfactant component includes TWEEN® Polysorbate 80. Additionally, as discussed above, it is contemplated that the ethanol component can be included as a surfactant or as a cosolvent. In this regard, it is noted that components added to the solution that are beyond the solubility limit of menthol may require a surfactant. Then, in a fourth step 4020, the nicotine salt/saline mixture from the second step 4010 is combined with the menthol/ethanol/surfactant mixture from the third step 4015 to create the target formulation for aerosolizing and inhaling using electronic devices. When a surfactant, such as TWEEN® Polysorbate 80, is used in the aqueous formulation, the sequence of preparation steps can help to prevent a constituent from precipitating as a solid during mixing of components. In particular, where menthol and a surfactant are both used in the aqueous formulation, combining the nicotine component and the acid component separately from the menthol component and the surfactant component helps to prevent menthol from precipitating out of the system when the separately combined components are mixed together to create the target formulation.

[0217] As discussed above, pH level measurements can be used to help inform regarding the fraction of different nicotine species in solution. pH level can also function as a gauge for overall sensory experience upon aerosolizing and inhaling an aqueous formulation. In contemplated embodiments, a target pH range for providing a pleasant sensory experience to users places the pH measurement of an aqueous formulation from approximately 2 to approximately 7. In at least some embodiments, a target pH value within a range of approximately 2 to approximately 5 is preferred. Furthermore, in at least some embodiments, a target pH value of approximately 3.38 reflects a particularly favorable sensory experience that mitigates harshness that may arise at higher nicotine concentrations.

[0218] Based on the foregoing description, it will be readily understood by those persons skilled in the art that the invention has broad utility and application. Electronic devices of the invention can be utilized to deliver liquids comprising supplements, drugs, or therapeutically effective amounts of pharmaceuticals using an aerosol having particles of a size that can easily be inhaled. The aerosol can be used, for example, by a patient within the bounds of an inhalation therapy, whereby the liquid containing a supplement, therapeutically effective pharmaceutical, or drug reaches the patient's respiratory tract upon inhalation. Desired compounds such as nicotine, flavoring, and supplements like B12, can be received by a person through inhalation without the toxic byproducts like formaldehyde—a recognized Group 1 Carcinogen for caner—that is currently being created during heating in conventional vapes. Electronic devices of the invention further can be used in the marijuana industries, but only where legal, for delivery of cannabinoids and CBD oils and the like. Moreover, many embodiments and adaptations of the invention other than those specifically described herein, as well as many variations, modifications, and equivalent arrangements, will be apparent from or reasonably suggested by the invention and the foregoing descriptions thereof, without departing from the substance or scope of the invention.

[0219] It further will be appreciated from the foregoing that at least some preferred embodiments of the invention represent a portable, orientation-agnostic vibrating mesh nebulizer. It further will be appreciated from the foregoing that at least some preferred embodiments emit an aerosol that is—sensorially speaking—equivalent to vapor, i.e., not a mist but instead that which is generated by traditional vapes, thereby providing an enjoyable consumer product for those who are accustomed to vaping.

[0220] Accordingly, while the invention has been described herein in detail in relation to one or more preferred embodiments, it is to be understood that this disclosure is only illustrative and exemplary of the invention and is made merely for the purpose of providing a full and enabling disclosure of the invention. The foregoing disclosure is not intended to be construed to limit the invention or otherwise exclude any such other embodiments, adaptations, variations, modifications or equivalent arrangements, the invention being limited only by the claims appended hereto and the equivalents thereof